◆ 会议时间：2025年3月19-22日
◆ 会议地点：荷兰 阿姆斯特丹

◆ 会议简介：

2025年第18届糖尿病先进技术与治疗国际会议（ATTD2025）将于2025年3月19-22日在荷兰阿姆斯特丹举行。国际糖尿病先进技术与治疗大会（ATTD）是一个独特的会议，为临床医生和科学家提供了一个世界级的平台，以介绍、讨论和交流快速发展的糖尿病技术和治疗领域的最新见解宣。ATTD将汇集该领域众多的国际一流专家，共同讨论糖尿病治疗方面的突破性技术创新成果，并展示新的胰岛素类似物、输送系统、泵、葡萄糖传感器、闭环系统等的最新进展。ATTD是与会者了解糖尿病最新研究进展的重要机会，预计有来自世界各地的2500余名代表参会。未经本站许可禁止复制摘录镜像转载本站任何内容-领域国际医学会议网（lingyuint.com）。

The 18th International Conference on Advanced Technologies & Treatments for Diabetes - ATTD 2025

Date:
19-22 March 2025

Venue:
Amsterdam, The Netherlands

Cutting-Edge Diabetes Breakthroughs
Innovation, novelties and advancement in diabetes treatment and technology. ATTD is the ultimate meeting to discover the latest worldwide research, devices and developments in the diabetes field.

Join us from 19-22 March 2025, in Amsterdam, The Netherlands, for the 18th International Conference on Advanced Technologies & Treatments for Diabetes.

Join the community of experts, clinicians, researchers, and industry professionals to stay up-to-date with the latest advancements in our field. Together, we can continue driving revolutionary changes and making a positive impact on those battling diabetes.

摘要征集：

点此提交摘要>>>Submit Abstract>>>

Please read the submission rules before submitting an abstract.

• Abstracts must be submitted online via the website only.
  ABSTRACTS SUBMITTED BY EMAIL WILL NOT BE ACCEPTED.
• Presentation Type: Abstracts may be submitted for oral, short oral or e-Poster. (Late breaking abstracts can only be submitted for e-Poster.)
  The Scientific Committee will determine whether the abstract will be accepted for presentation, with consideration given to the author’s preference.
• Abstracts must be received by the announced deadline. Abstracts received after the deadline will not be considered.
• The submission system automatically defines the abstract submitter as a co-author. This cannot be changed after the submission.
  Note if you are not a co-author and are submitting on someone else’s behalf, please use their username and login details to submit the abstract.  

Limitations

• The same person may submit up to 5 abstracts regardless of presenting author.
• The same person may serve as a presenting author on up to 3 abstracts.
• Presenting authors must be registered participants. Only abstracts of authors who have paid their registration fees by the deadline indicated in the notification email, will be scheduled for presentation and included for publication.
• Submission of an abstract acknowledges your acceptance for the abstract to be published in the official Conference publications.
• The presenting author is required to ensure that all co-authors are aware of the content of the abstract and agree to its submission, before submitting the abstract.
• Previously Presented/Published Policy: Abstracts that have been previously presented at another meeting may be submitted.
• All accepted abstracts will be published in the peer-reviewed journal Diabetes Technology & Therapeutics, published by Mary Ann Liebert, Inc., Publishers. The Journal is indexed in PubMed.
• The Abstract Submitter grants the Organizers a royalty-free, perpetual, irrevocable nonexclusive license to use, reproduce, publish, translate, distribute, and display the content.
• Abstracts must be submitted in English.
  All abstracts should be submitted and presented in clear English with accurate grammar and spelling of a quality suitable for publication. If you need help, please arrange for the review of your abstract by a colleague who is a native English speaker, by a university specific publications office (or other similar facility) or by a copy editor, prior to submission.
• Disclosure of Conflicts of Interest: Abstract submitters will be required to disclose any conflict of interests in the submission form.

Instructions for preparation of presentations will be made available on the conference website in due course.

Guidelines for Submission

​Before you begin, please prepare the following information:

• ​Presenting author’s contact details:
  – Full first and family name(s)
  – Email address
  – Affiliation details: department, institution / hospital, city state (if relevant), Country
  – Phone number
• Author and co-authors’ details
• Preferred Presentation type: Oral Presentation / Short Oral Presentation / e-Poster
• Abstract title – must be in UPPER CASE and limited to 25 words. Please submit symbols as words.
• Abstract text – limited to 250 words including acknowledgments. (Please Note: word count is affected when graphs/tables are included).
• Abstract topic– select the abstract topic per the list of topics.
• Images– The maximum file size of each image is 500 KB. The maximum pixel size of the graph/image is 600(w) x 800(h) pixel. You may upload images in JPG, GIF or PNG format. Note: images don’t affect the word count.
• Abstracts should clearly state:
  Background and aims
  Methods
  Results
  Conclusions 
• Use only standard abbreviations. Place special or unusual abbreviations in parentheses after the full word the first time it appears.
• Use generic names of drugs. The presentation must be balanced and contain no commercial promotional content.
• Submissions may not contain patient names, hospital ID numbers or other identifying information.
• The submission form allows you to store your abstract as a DRAFT until the deadline. After the deadline if not submitted, drafts will be deleted.
• Click on the SUBMIT button at the end of the process in order to save your abstract. You may log in to the system later to make changes to your abstract, up to the submission deadline. After the deadline, abstracts cannot be modified or corrected.
• You will receive an abstract ID number via email after you have submitted your abstract. Please refer to this abstract number in all correspondence regarding the abstract.
• Please contact us if you have not received confirmation that your abstract has been submitted.
• Please do not submit multiple copies of the same abstract.

Abstract Submitters’ Declaration

During abstract submission you will be asked to confirm that you agree to the following:

1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after final submission and I am aware that it will be published exactly as submitted.
2. Submission of the abstract constitutes the consent of all authors to publication (e.g. Conference website, programs, other promotions, etc.)
3. The Abstract Submitter warrants and represents that no part of the information and content provided by him/her (Hereafter: the “Content“) to ATTD 2024 and Kenes International (Hereafter: the “Organizers“), nor the publication of any such Content by the Organizers, on the internet or otherwise infringes any third party rights, including but not limited to  intellectual property rights.
4. The Abstract Submitter grants each of the Organizers the license and right to use, reproduce, publish, translate, distribute, and display the Content or any part thereof, in any manner and on any platform or media whatsoever, in each Organizer’s absolute discretion, on a royalty-free, perpetual, irrevocable nonexclusive basis.
5. I herewith confirm that the contact details saved in this system are those of the presenting author, who will be notified about the status of the abstract. The presenting author is responsible for informing the other authors about the status of the abstract. The submitting author may request to be copied on abstract correspondence.
6. I understand that the presenting author must be a registered participant.
7. The Organizers reserve the right to remove from publication and/or presentation an abstract which does not comply with the above.
8. I understand that I must select a specific Theme, Topic and/or Sub-Topic for my abstract allocation.  Although the Committee will work hard to honor this selection, this cannot be guaranteed.  The Committee reserves the right to change the Theme, Topic or Sub-Topic under which the abstract was originally submitted.
9. I confirm to have received the consent of all authors for the processing of their contact details by Kenes and the Organizers.

Dear Colleagues,

On behalf of the Organizing Committee, we are thrilled to extend a warm welcome to the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2025), scheduled to take place from 19-22 March, 2025, in Amsterdam, The Netherlands.

We invite you to join us at ATTD, the premier international platform, where clinicians, diabetes care providers, researchers, industries, startups, investors, reimbursement authorities, regulators, and individuals living with diabetes convene with the shared aim of enhancing diabetes care at an accelerated pace.

The conference will feature presentations and discussions led by esteemed professionals in the field, covering a diverse range of topics including artificial intelligence-driven decision support systems, glucose sensors, closed-loop systems, artificial pancreas technology, screening, intervention and prevention of type 1 diabetes, preventive devices for diabetes, new medications, innovative insulin delivery systems and many more.

ATTD 2025 promises to be an outstanding event and we will be happy to meet you in the magnificent city of Amsterdam.

Yours sincerely,

Professor Moshe Phillip | Professor Tadej Battelino
Conference Chairpersons

注册费：

In-Person Participation Fees (in EUR) apply to payments received prior to the indicated deadlines.

Online Participation Fees (in EUR) apply to payments received prior to the indicated deadlines.

* Proof of Student/Fellow/Nurse/Dietitian status is mandatory – In order to benefit from the special fee, a submission of your status confirmation (approval letter signed by the Head of Department or copy of your status ID) must be uploaded during the Online registration.

** FLEX Want to attend in-person, but concerned your ability to travel may change? Purchase Flex with your In-Person registration for the freedom to convert to Online registration any time before the meeting and receive a refund of the difference in fees.

EU national legislation and codes of practice prohibit the advertising of prescription-only medicines to individuals not licensed/authorized to prescribe or supply ‘prescription medicines’, apply (Medicines for Europe Code. Article 4.1. Non-promotion of prescription-only medicines).

In order to prevent these groups from being actively approached with advertising, they will be identified as such.

PLEASE NOTE: If registration includes membership, make sure link is also shared with the Association Manager and Membership Manager to review and check before launch!

Fees for in-person participants include:

• Participation in all scientific sessions.
• Opening Ceremony and Welcome Reception.
• Access to the Exhibition Area.
• Refreshments during coffee breaks as indicated in the program.
• Dedicated time and place for Networking.
• Delegate bag including all conference printed material
• ATTD 2024 Yearbook Online
• Open access to the ATTD Virtual Platform where Live sessions will be streamed during the conference days. The session recordings will be available, after the conference to ATTD delegates for 3 months, on Unlok. New to ATTD on UNLOK? Please create your free account here. (important note: please register to UNLOK with the same email as your ATTD25 Registration)

Fees for online category include:

• Open access to the ATTD Virtual Platform where Live sessions will be streamed during the conference days. The session recordings will be available, after the conference to ATTD delegates for 3 months, on Unlok. New to ATTD on UNLOK? Please create your free account here. (important note: please register to UNLOK with the same email as your ATTD25 Registration)
• Earn CME credits. Participate in the scientific program and be eligible to receive the number of CME credits attributed to the virtual meeting.
• Access all the e-posters. Browse research on the hottest topics published in the congress digital abstract book and connect with the abstract authors and other colleagues from around the world through the e-poster virtual consultations and ATTD 2024 Yearbook Online.

◆ 参会对象：医生、医院科室主任/副主任、住院医师、医院管理者、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。